



WORLD ACADEMIC FRONTIERS
世界学术研究前沿丛书

Tumor Research

肿瘤研究

“世界学术研究前沿丛书”编委会
THE EDITORIAL BOARD OF
WORLD ACADEMIC FRONTIERS





WORLD ACADEMIC FRONTIERS
世界学术研究前沿丛书

Tumor Research

肿瘤研究

“世界学术研究前沿丛书”编委会
THE EDITORIAL BOARD OF
WORLD ACADEMIC FRONTIERS

 中国出版集团公司
 世界图书出版公司
广州·上海·西安·北京

图书在版编目 (CIP) 数据

肿瘤研究: 英文 / “世界学术研究前沿丛书”编委会编. —广州: 世界图书出版广东有限公司, 2017.8
ISBN 978-7-5192-2461-5

I. ①肿… II. ①世… III. ①肿瘤—研究—英文
IV. ①R73

中国版本图书馆 CIP 数据核字 (2017) 第 040982 号

Tumor Research © 2016 by Scientific Research Publishing

Published by arrangement with Scientific Research Publishing
Through Wuhan Irvine Culture Company

This Edition © 2017 World Publishing Guangdong Corporation
All Rights Reserved.
本书仅限中国大陆地区发行销售

书 名: 肿瘤研究
Zhongliu Yanjiu
编 者: “世界学术研究前沿丛书”编委会
责任编辑: 张柏登 康琬娟
出版发行: 世界图书出版广东有限公司
地 址: 广州市海珠区新港西路大江冲25号
邮 编: 510300
电 话: (020) 84460408
网 址: <http://www.gdst.com.cn/>
邮 箱: wpc_gdst@163.com
经 销: 新华书店
印 刷: 广州市德佳彩色印刷有限公司
开 本: 787 mm×1092 mm 1/16
印 张: 49
插 页: 4
字 数: 930千
版 次: 2017年8月第1版 2017年8月第1次印刷
国际书号: ISBN 978-7-5192-2461-5
定 价: 598.00元

版权所有 翻印必究
(如有印装错误, 请与出版社联系)

Preface

Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer. Cancers are best managed by discussing in multi-disciplinary tumor board where medical oncologist, surgical oncology, radiation oncology, pathologist, radiologist and organ specific oncologists meet to find the best possible management for an individual patient considering the physical, social, psychological, emotional and financial status of the patients. It is very important for oncologists to keep updated of the latest advancements in oncology as changes in management of cancer are quite common.¹ Those who are interested in the field of oncology could read reviews and original articles in this book to gain a more systematic understanding of oncology.

In the present book, thirty typical literatures about oncology published on international authoritative journals were selected to introduce the worldwide new progress, which contains reviews or original researches on medical science, oncology, genome biology, cytology, *ect.* We hope this book can demonstrate advances in oncology as well as give references to the researchers, students and other related people.

编委会:

- ✧ 伊娃·科里教授, 华盛顿大学, 美国
- ✧ 马库斯·J·赛贝尔教授, 悉尼大学, 澳大利亚
- ✧ 艾吉斯·西里瓦得纳教授, 曼彻斯特大学, 英国
- ✧ 詹姆斯教授, 香港大学, 中国
- ✧ 彼得·K·N, 于教授, 香港城市大学, 中国
- ✧ 李亚明教授, 博士生导师, 中国医科大学, 中国

March 9, 2017

¹From Wikipedia: <https://en.wikipedia.org/wiki/Oncology>

Selected Authors

Elaine Mardis, The Genome Institute at Washington University, Washington University, School of Medicine, 4444 Forest Park Blvd, St Louis, USA.

Debu Tripathy, University of Southern California, Keck School of Medicine, USC/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, NTT-3429, Los Angeles, USA.

Cihan Cetinkaya, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

Bo Li, Program of Bioinformatics, University of Michigan, 5940A Buhl, Box 5618, Ann Arbor, USA.

Angabin Matin, Department of Genetics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

Kenneth Miles, Department of Diagnostic Imaging Princess Alexandra Hospital, Institute of Nuclear Medicine University College London, UK.

Michael Orth, Department of Radiotherapy and Radiation Oncology Ludwig-Maximilians-University of Munich, Germany.

Ralf Gallasch, Biocenter, Division of Bioinformatics, Innsbruck Medical University, Innsbruck, Austria.

Silvia Morbelli, PhD, Nuclear Medicine Unit, IRCCS AOU San Martino-IST, Department of Health Sciences, University of Genoa, Genoa, Italy.

Franco M. Buonaguro, Division of Molecular Biology & Viral Oncology,
Department of Experimental Oncology Istituto Nazionale Tumori -IRCCS “Fond
Pascale”, France.

Contents

Preface.....I

Selected Authors.....III

Chapter 1.....1
Tumor Heterogeneity: Next-Generation Sequencing Enhances the View
from the Pathologist’s Microscope
by Samuel Aparicio and Elaine Mardis

Chapter 2.....9
Next Generation Sequencing and Tumor Mutation Profiling: Are We
Ready for Routine Use in the Oncology Clinic?
by Debu Tripathy, Kathleen Harnden, Kimberly Blackwell, et al.

Chapter 3.....27
Age Dependence of Tumor Genetics in Unfavorable Neuroblastoma:
ArrayCGH Profiles of 34 Consecutive Cases, Using a Swedish 25-Year
Neuroblastoma Cohort for Validation
by Cihan Cetinkaya, Tommy Martinsson, Johanna Sandgren, et al.

Chapter 4.....55
A General Framework for Analyzing Tumor Subclonality Using SNP
Array and DNA Sequencing Data
by Bo Li and Jun Z. Li

Chapter 5.....105
Oncogenes and Tumor Suppressor Genes: Comparative Genomics and Network Perspectives
by Kevin Zhu, Qi Liu, Yubo Zhou, et al.

Chapter 6.....127
Tumor Loci and Their Interactions on Mouse Chromosome 19 That Contribute to Testicular Germ Cell Tumors
by Rui Zhu and Angabin Matin

Chapter 7.....153
Familial Testicular Germ Cell Tumor: No Associated Syndromic Pattern Identified
by Christine M. Mueller, Larissa A. Korde, Mary L. McMaster, et al.

Chapter 8.....171
Integrating Genetics and Epigenetics in Breast Cancer: Biological Insights, Experimental, Computational Methods and Therapeutic Potential
by Claudia Cava, Gloria Bertoli and Isabella Castiglioni

Chapter 9.....265
A Joint Analysis of Metabolomics and Genetics of Breast Cancer
by Xiaohu Tang, Chao-Chieh Lin, Ivan Spasojevic, et al.

Chapter 10.....297
Aberrant PTPRO Methylation in Tumor Tissues as a Potential Biomarker That Predicts Clinical Outcomes in Breast Cancer Patients
by Shao-ying Li, Rong Li, Yu-li Chen, et al.

Chapter 11.....321
New Concepts in Breast Cancer Genomics and Genetics
by Rodrigo Goncalves, Wayne A. Warner, Jingqin Luo, et al.

Chapter 12.....	345
Obtaining Informed Consent for Clinical Tumor and Germline Exome Sequencing Of Newly Diagnosed Childhood Cancer Patients <i>by Sarah Scollon, Katie Bergstrom, Robin A Kerstein, et al.</i>	
Chapter 13.....	369
Primer on Tumor Immunology and Cancer Immunotherapy <i>by Timothy J. Harris and Charles G. Drake</i>	
Chapter 14.....	391
Diagnosis and Treatment of Solid Pseudopapillary Tumor of the Pancreas: Experience of One Single Institution from Turkey <i>by Ayşe Yagc, Savas Yakan, Ali Coskun, et al.</i>	
Chapter 15.....	405
Multiple Tumor Marker Protein Chip Detection System in Diagnosis of Pancreatic Cancer <i>by Fangfeng Liu, Futian Du and Xiao Chen</i>	
Chapter 16.....	415
Serum Irisin Levels Are Lower In Patients With Breast Cancer: Association With Disease Diagnosis And Tumor Characteristics <i>by Xenı Provatopoulou, Georgia P. Georgiou, Eleni Kalogera, et al.</i>	
Chapter 17.....	439
A Mutation Screening of Oncogenes, Tumor Suppressor Gene TP53 and Nuclear Encoded Mitochondrial Complex I Genes in Oncocytic Thyroid Tumors <i>by Cecilia Evangelisti, Dario de Biase, Ivana Kurelac, et al.</i>	
Chapter 18.....	457
Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain <i>by Laia Domingo, Dolores Salas, Raquel Zubizarreta, et al.</i>	

Chapter 19.....481
The Clinical Trial Landscape in Oncology and Connectivity of Somatic
Mutational Profiles to Targeted Therapies
by Sara E. Patterson, Rangjiao Liu, Cara M. Statz, et al.

Chapter 20.....507
Advancing Clinical Oncology through Genome Biology and Technology
by Anna M. Varghese and Michael F. Berger

Chapter 21.....523
Evidence-Based Medicine and Clinical Fluorodeoxyglucose PET/MRI
in Oncology
by Kenneth Miles, Liam McQueen, Stanley Ngai, et al.

Chapter 22.....541
Current Concepts in Clinical Radiation Oncology
by Michael Orth, Kirsten Lauber, Maximilian Niyazi, et al.

Chapter 23.....607
Scenario Drafting for Early Technology Assessment of Next Generation
Sequencing in Clinical Oncology
by S.E.P. Joosten, V.P. Retèl, V.M.H. Coupé, et al.

Chapter 24.....629
Mathematical Models for Translational and Clinical Oncology
by Ralf Gallasch, Mirjana Efremova, Pornpimol Charoentong, et al.

Chapter 25.....649
Associations between Clinical and Sociodemographic Data and Patterns
of Communication in Pediatric Oncology
by Marina Kohlsdorf and Áderson Luiz Costa Junior

Chapter 26.....	669
Contrast-Enhanced [^{18}F] Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Clinical Oncology: Tumor-, Site-, and Question-Based Comparison with Standard Positron Emission Tomography/Computed Tomography <i>by Silvia Morbelli, Raffaella Conzi, Claudio Campus, et al.</i>	
Chapter 27.....	695
Lack of Timely Accrual Information in Oncology Clinical Trials: A Cross-Sectional Analysis <i>by Aaron P. Mitchell, Bradford R. Hirsch and Amy P. Abernethy</i>	
Chapter 28.....	707
Testing the Treatment Effect on Competing Causes of Death in Oncology Clinical Trials <i>by Federico Rotolo and Stefan Michiels</i>	
Chapter 29.....	731
Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update <i>by Abram Recht, Elizabeth A. Comen, Richard E. Fine, et al.</i>	
Chapter 30.....	765
Clinical Oncology in Resource-Limited Settings <i>by Franco M. Buonaguro, Serigne N. Gueye, Henry R. Wabinga, et al.</i>	

Chapter 1

Tumor Heterogeneity: Next-Generation Sequencing Enhances the View from the Pathologist's Microscope

Samuel Aparicio^{1,2}, Elaine Mardis³

¹Department of Molecular Oncology, BC Cancer Agency, 675 W10th Avenue, V5Z 1L3 Vancouver, British Columbia, Canada

²Nan and Lorraine Robertson Chair, Canada Research Chair, Department of Pathology and Laboratory Medicine, University of British Columbia, V6T 2B5 Vancouver, British Columbia, Canada

³The Genome Institute at Washington University, Washington University School of Medicine, 4444 Forest Park Blvd, St Louis, MO 63108, USA

Abstract: The term heterogeneity covers many aspects of the variability in tumor phenotypes, which are a characteristic of human malignancies. Morphologists of the late 19th century first described the multiple cell types composing tumors and began to recognize cancers of different types. Over the past half century the molecular underpinnings of the variability in human cancers has been gradually revealed but within the last 5 years there has been an explosion in our ability to determine and learn from cancer heterogeneity, through the use of next-generation sequencing and related methods. The complexity and variation in the structure of cancers can seem daunting, but important lessons in cancer biology and the ap-

proaches to therapy can be learned from studying how much of the complexity is subject to change and how much is a consequence of stochastic rather than deterministic processes. The evolution of clones, individual variation in response to therapy, distinct biological subtypes of cancer and tumor immune responses are all examples of the heterogeneous nature of human cancers. Self evidently, when heterogeneity is used to describe any aspect of a cancer, it is important to know which variational feature is being addressed.

1. Experimental Approaches to Heterogeneity

A review by Hiley *et al.*^[1] sets the stage for the research studies of heterogeneity published in this special issue, by updating the reader regarding how the use of next-generation sequencing and clever experimental design have increased our understanding of genomic and regional heterogeneity in cancers. The special collection provides several research-based studies of tumor heterogeneity, encompassing the variation between individuals (the tumor subtype) in breast cancers (Ali *et al.*^[2]) and, by contrast, the lessons that can be learned from longitudinal study of single patient ("N of 1") cases (Fisher *et al.*^[3], Nadauld *et al.*^[4]). These studies provide contrasts between the approaches needed to determine disease groupings in populations, where many hundreds or thousands of patients must be studied, with the approaches to pursuing the moving target of individual cancers. The latter can be effectively studied in smaller numbers with informative consequences when evolution is used to sift the features undergoing selection and fixation. An Opinion piece by Good *et al.*^[5] provides a scientific and philosophical perspective on the N of 1 paradigm.

2. Methodological Approaches to Heterogeneity

Of equal importance to the experimental approaches used to study heterogeneity are the methods used to evaluate heterogeneity across the spectrum of variation that can be measured in cancer by different assay types. These encompass next-generation sequencing methods for analyzing tumor and normal cell composition, the analysis of clonal populations in cancers (Qiao *et al.*^[6]), and methods addressing epigenetic plasticity (Zheng *et al.*^[7]). Hence, several important tools and approaches are presented that facilitate answering critical questions about he-

terogeneity, and an opinion piece contributed by Russnes *et al.*^[8] advocates for data integration to better interpret heterogeneity data.

3. Single Cell Approaches to Heterogeneity

Resolving structure and function with single cell approaches is also becoming important, both in studies of clonality as well as for functional assessment of tumor cell populations. Learning how to reconcile whole tumor cell-based population approaches with the single cell data will be important. Nicholas Navin's review^[9] of single cell sequencing in cancer studies provides a survey of this rapidly developing area.

4. RNA-Based Studies of Heterogeneity

Next-generation sequencing-based studies of RNA populations from cancer cells are revealing important aspects of transcriptional activity and its role in cancer. A review by Patrick Nana-Sinkam and Carlo Croce^[10] sets the stage by discussing the role of microRNAs in gene regulation in cancers. White *et al.*^[11] present important new descriptions of long non-coding RNAs (lncRNAs) in lung cancers, and Wyatt *et al.*^[12] describe transcriptomes in the context of therapy response in high-risk prostate cancers. The method for detecting allele-specific expression contributed by Mayba *et al.*^[13] will also yield important insights into which variants detected by DNA sequencing are actually being expressed in the transcriptome of cancer cells. The role of the epigenome in contributing to the patterning of transcriptomes and the possibility of modulating RNA expression is emphasized in three primary research articles exploring this aspect of tumor heterogeneity (Lund *et al.*^[14], Fleischer *et al.*^[15], and Charlton *et al.*^[16]).

5. Clinical Aspects of Heterogeneity

As our underlying knowledge about cancer genomics and heterogeneity improves, the need to translate this information into informed cancer care for patients is an obvious next step. Berger and Varghese have contributed an Opinion piece^[17] to describe the translation of cancer genomics in the clinic, and contributions from

de Bono^[18] and Bardelli^[19] outline the use of circulating tumour cells (CTCs) and circulating free DNA (cfDNA), respectively, as approaches to monitoring tumor progression. These blood-based or “liquid biopsy” approaches present an exciting new paradigm in contrast to conventional and less sensitive imaging-based approaches to monitor patients. Deininger also reviews^[20] an important area to clinical therapeutics that is often identified by genomic information, providing an overview of therapy response and resistance to targeted therapies. The genomic variability between patients is highlighted in the research article of Ali *et al.*^[21], delineating molecular subtypes in large cohorts of breast cancer patients.

6. Data and More Data

Finally, in the genomic era, sharing of data and complete descriptions of analytic methods, to the level of providing code in addition to data, will prove crucial to continued success. Boutros *et al.*^[21] provide a novel look at crowd-sourcing algorithms for cancer analysis, and Bartha Knoppers and colleagues^[22] present a critically important Opinion regarding the legal framework for genomic data sharing. Hence, the special collection provides a wide-ranging overview of cancer heterogeneity in its many manifestations, from fundamental methods-based approaches to study heterogeneity to the use of genomic information for response and progression monitoring. We think the breadth of cancer studies that have been impacted by next generation sequencing, including improved understanding and characterization of cancer heterogeneity, is setting the stage for major breakthroughs in our biological understanding of this vexing and complicated disease.

Competing Interests

The authors declare that they have no competing interests.

Acknowledgements

The guest editors would like to gratefully acknowledge the gracious and insightful contributions from all the authors who wrote reviews, opinions, or primary research manuscripts for the collection. We would also like to thank Rafal Mars-

zalek for his tireless assistance, his encouragement, and his invaluable input toward the content of this special issue. Dr Mardis would like to acknowledge NIH/NHGRI 5U54HG003079 for support. Dr Aparicio is supported by the Canada Research Chairs program and the BC Cancer Foundation.

Source: Aparicio S, Mardis E. Tumor heterogeneity: next-generation sequencing enhances the view from the pathologist's microscope. [J]. *Genome Biology*, 2014, 15(9):463–463.

References

- [1] Hiley C, de Bruin EC, Mc Granahan N, Swanton C: Deciphering intra-tumor heterogeneity and temporal acquisition of driver events to refine precision medicine. *Genome Biol* 2014, 15:453.
- [2] Ali HR, Rueda OM, Chin SF, Curtis C, Dunning MJ, Aparicio SAJR, Caldas C: Genome-driven integrated classification of breast cancer validated in over 7,500 samples. *Genome Biol* 2014, 15:431.
- [3] Fisher R, Horswell S, Rowan A, Salm M, De Bruin E, Gulati S, McGranahan N, Stares M, Gerlinger M, Varela I, Crockford A, Favero F, Quidville V, Andre F, Navas C, Gronroos E, Nicol D, Hazell S, Hrouda D, O'Brien T, Matthews N, Phillimore B, Begum S, Rabinowitz A, Biggs J, Bates PA, McDonald NQ, Stamp G, Spencer-Dene B, Hsieh JJ, *et al*: Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. *Genome Biol* 2014, 15:433.
- [4] Nadauld LD, Garcia S, Natsoulis G, Bell JM, Miotke L, Hopmans ES, Xu H, Pai RK, Palm C, Regan JF, Chen H, Flaherty P, Ootani A, Zhang NR, Ford JM, Kuo CJ, Ji HP: Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. *Genome Biol* 2014, 15:428.
- [5] Good BM, Ainscough BJ, McMichael JF, Su AI, Griffith OL: Organizing knowledge to enable personalization of medicine in cancer. *Genome Biol* 2014, 15:438.
- [6] Qiao Y, Quinlan AR, Jazaeri AA, Verhaak RGW, Wheeler DA, Marth GT: SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. *Genome Biol* 2014, 15:443.
- [7] Zheng X, Zhao Q, Wu HJ, Li W, Wang H, Meyer CA, Qin QA, Xu H, Zang C, Jiang P, Li F, Hou Y, He J, Wang J, Wang J, Zhang P, Zhang Y, Liu XS: MethylPurify: tumor purity deconvolution and differential methylation detection from single tumor DNA methylomes. *Genome Biol* 2014, 15:419.
- [8] Russnes HG, Lønning PE, Børresen-Dale AL, Lingjærde OC: The multitude of molecular analyses in cancer: the opening of Pandora's box. *Genome Biol* 2014, 15:447.

- [9] Navin NE: Cancer genomics: one cell at a time. *Genome Biol* 2014, 15:452.
- [10] Nana-Sinkam SP, Croce CM: MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use. *Genome Biol* 2014, 15:445.
- [11] White NM, Cabanski CR, Fisher-Silva JM, Dang HX, Govindan R, Maher CA: Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. *Genome Biol* 2014, 15:429.
- [12] Wyatt AW, Mo F, Wang K, McConeghy B, Brahmabhatt S, Jong L, Mitchell DM, Johnston RL, Haegert A, Li E, Liew J, Yeung J, Shrestha R, Lapuk A, McPherson A, Shukin R, Bell RH, Anderson S, Bishop J, Hurtado-Coll A, Xiao H, Chinnaiyan AM, Mehra R, Lin D, Wang Y, Fazli L, Gleave ME, Volik SV, Collins CC: Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. *Genome Biol* 2014, 15:426.
- [13] Mayba O, Gilbert HN, Liu J, Haverty PM, Jhunjhunwala S, Jiang Z, Watanabe C, Zhang Z: MBASED: allele-specific expression detection in cancer tissues and cell lines. *Genome Biol* 2014, 15:405.
- [14] Lund K, Cole J, VanderKraats ND, McBryan T, Pchelintsev NA, Clark W, Copland M, Edwards JR, Adams PD: DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML. *Genome Biol* 2014, 15:406.
- [15] Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis MLH, Haakensen V, Wärnberg F, Naume B, Helland Å, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN: Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. *Genome Biol* 2014, 15:435.
- [16] Charlton J, Williams RD, Weeks M, Sebire NJ, Popov S, Vujanic G, Mifsud W, Alcaide-German M, Butcher LM, Beck S, Pritchard-Jones K: Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood. *Genome Biol* 2014, 15:434.
- [17] Varghese AM, Berger MF: Advancing clinical oncology through genome biology and technology. *Genome Biol* 2014, 15:427.
- [18] Mateo J, Gerlinger M, Rodrigues D, de Bono JS: The promise of circulating tumor cell analysis in cancer management. *Genome Biol* 2014, 15:448.
- [19] Siravegna G, Bardelli A: Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. *Genome Biol* 2014, 15:449.
- [20] Eiring AM, Deininger MW: Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. *Genome Biol* 2014, 15:461.
- [21] Boutros PC, Margolin AA, Stuart JM, Califano A, Stolovitzky G: Toward better benchmarking: challenge-based methods assessment in cancer genomics. *Genome*